Key result
A review of the literature highlights the pharmacogenetic risks and underlying mechanisms of commonly prescribed channel-modulating drugs in patients with inherited cardiac sodium channel diseases.
Why the study?
What are the pharmacogenetic effects and risks of cardiac Na channel-modulating drugs in patients with inherited Na channel-related diseases?
What are the pharmacogenetic effects and risks of cardiac Na channel-modulating drugs in patients with inherited Na channel-related diseases?
This review highlights the pharmacogenetic risks of prescribing cardiac sodium channel-modulating drugs to patients with inherited sodium channelopathies like long QT syndrome type 3 and Brugada syndrome.
Answers are grounded in this paper and cite their sources.
May support avoiding certain channel-modulating drugs in sodium channelopathy patients; hypothesis-generating for prospective pharmacogenetic validation.
Sodium (Na) channels are essential for cardiac electrical activity. Cardiac Na channel dysfunction, inherited or acquired, can induce life-threatening conduction and arrhythmia disorders. Inherited Na channel dysfunction may put affected patients at a greater risk for these complications when channel-modifying drugs are prescribed. This study addressed pharmacogenetic effects in three well-described Na channel-related diseases: long QT syndrome type 3, Brugada syndrome and inherited cardiac conduction disease. A review of the currently available literature on cardiac Na channel-modulating drugs was undertaken. An overview is given of the known risks of development of the previously mentioned complications of commonly prescribed drugs in patients affected with Na channel-related diseases and the underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
SMITS et al. (2008) conducted a review in Inherited cardiac sodium channel diseases (long QT syndrome type 3, Brugada syndrome, inherited cardiac conduction disease). Cardiac sodium channel-modulating drugs was evaluated. A review of the literature highlights the pharmacogenetic risks and underlying mechanisms of commonly prescribed channel-modulating drugs in patients with inherited cardiac sodium channel diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: